Member Info for Diversified

I found the webcast that followed the last prelims extremely useful and one of the best webcasts I have listened to by the company to date. Of particular use was the analyst Q&A at the end which contained some really important questions, primarily the commercial questions that would assist valuation.

If they were aware of the outcome at this point the market would of bent their arm into a price sensitive RNS at this point, it either flows or it doesn’t, and if it doesn’t then that would of been reported in conjunction with today’s RNS. To what rate is the average flow, now that can be stringed out in accordance with their 2 week testing plan which was communicated to the market last year.

Still looking good imo, especially when all these specialists cost money.

Serious bottleneck of news building for 2021

FDA application submission ?
Global launch of labs ?
AIR submission
PD-L1 assay
Pharma services contract(s)
Sample to answer upgrade
Ovarian Cancer results
FDA approval
Collaboration(s)
Clear lab Validation
Ovarian Assay
Nasdaq listing

Just wait for the crowd to arrive. Sleeping giant.

Communication from the company to date implies UK lab is on track for Q1 as per previous guidance. US lab Q2.

It would be transformational and a further endorsement of the mind blowing potential of this company. Other companies name checked and worth keeping an eye on in addition to the Abbott HER2 partnership would be:

‘The investigation of PDL1 is a key target for leading immunotherapy drugs such as Pembrolizumab (also known as Keytruda from Merck), Nivolumab (also known as Opdivo from BMS), Durvalumab (also known as Imfinzi from AstraZeneca) and Atezolizumab (also known as Tecentriq from Roche). As of September 2019, there were 2,975 active drug trials targeting PDL1 (and the receptor to which it binds, PD1), planning to recruit over 500,000 patients. Thus, there is a need for an effective biomarker strategy to identify responding patients (Source: https://www.nature.com/articles/d41573-019-00182-w), which we believe the Parsortix system is now capable of meeting.’

Anyone of which would confirm the corporate adoption of Parsortix as a major player.

https://oncologypro.esmo.org/meeting-resources/european-lung-cancer-virtual-congress-2021/studying-tumour-heterogeneity-of-primary-non-small-cell-lung-cancer-in-humans-and-mice-pdx

As an extension to the link you kindly provided it is clear to see that this is related to the following RNS:

https://uk.advfn.com/stock-market/london/angle-AGL/share-news/Angle-PLC-LUNG-CANCER-STUDY-USES-ANGLES-PARSORTIX/79684162

Interestingly as Astrazeneca, referred to as a leading customer in the RNS makes reference to the the inclusion of ctDNA, it is reasonable to assume that in addition to Parsortix being the only CTC platform being used in this study that an ongoing partnership between AZN and Guardant Health could be the other system for the purpose of ctDNA:

https://www.globenewswire.com/news-release/2018/12/13/1666887/0/en/Guardant-Health-Partners-with-AstraZeneca-to-Develop-Blood-Based-Companion-Diagnostic-Tests-for-Tagrisso-and-Imfinzi.html

Under the terms of this deal GH went on to see a material move in its share price rising from $35 to $97 at its peak and we can all see what has happened since. Not bad for a multi billion dollar company which is unable to offer protein and RNA analysis like AGL, but the exact reason why Parsortix is a useful companion for these major companies.

We then consider AGL latest RNS concerning AZN:

https://uk.advfn.com/stock-market/london/angle-AGL/share-news/Angle-PLC-Parsortix-Dynamic-assessment-of-patient/84266695

And more specifically AZN's drug Tagrisso which is otherwise a culmination and report on all of the above. What this e-poster and coverage will promise to do is further enhance the Parsortix reputation and help build important new business relationships.

In my opinion a deal similar to that of Guardant Health deal in 2018 is more than possible and is perhaps the large Pharma contract that AN recently referred to being announced shortly in a recent presentation.

This isn’t aimed at anyone in particular.

For those that have taken the time to contact the company you would know that current balance sheet takes them to mid 2022 with ability to extend this by reducing discretionary spend. Any doubts, it’s worth contacting company as some will try to use this to their advantage short term to try to manipulate stock.

It is my opinion that next raise will coincide with Nasdaq listing which in turn is dependent on to
I think of FDA decision. This will reduce any dilution but also allow access to deep pool funding.

https://twitter.com/colebrooke1/status/1372093754665009153?s=21

Expecting a continuation of a very strong move.

Income is separate from capital gain tax. But please seek professional advice as I am not qualified to provide. ;-)

Only if your total gain is outside of annual CGT allowance. Gains are not realized until sold.

I honestly don’t understand why some will wait until the 6th April to use their tax allowance when you can simply ‘bed and isa’ for which the 30 day rule means that the sale and repurchase of shares during this period count as the same asset and therefore do not qualify for Capital Gains Tax.

For me this is what has presented such an intriguing opportunity at these levels. Many have reduced their position or exited in anticipation of lower prices and in all honesty they have discounted the impact of upcoming commercial catalysts such as the labs and ovarian results.

Labs

Research based revenue expected to be high single digit millions. Pharma services revenue high enough to cover entire corporate costs within circ. 5 years and then you have the clear lab assays such as breast and ovarian which are multi Billion dollar opportunities.

We are to receive an update on the Pdl-1 assay which again is another massive market opportunity, all of which feeds into large Pharma contracts.

A temporary spike, not for me, commercial progress is what the market has been waiting for, it’s the start of a very exciting story.

Bargain

https://www.ii.co.uk/analysis-commentary/five-aim-shares-generate-long-term-growth-your-isa-ii515418?utm_source=newsletter&utm_medium=email&utm_campaign=NEW-WKLY-ENGAGE-ii_weekend_round_up_130321&utm_content=newsletter&spMailingID=12516547&spUserID=MTIxNjc3MzUyMDYxS0&spJobID=1712827452&spReportId=MTcxMjgyNzQ1MgS2&fbclid=IwAR36lLi-ieQqBMUdcrqmv6ghSlfNlJoZK8xnOXUsK-ULdRVXYYK1v7D-_wY

Which is the current ovarian cancer test of choice for many including NHS and costs $200 a test or more, it has a lower specificity and sensitivity than Parsortix, so in theory it should be relatively straight forward to gain market share for this diagnostic.

Breast cancer test HER2 trial was also designed to satisfy CE approval and an application for this will be made shortly after FDA approval.

Verification study is due Q2 and as far as I’m aware June. Company will aim to launch assay by year end.

In all honesty the little volume on the OTC listing has little relevance at this stage but I do believe the Nasdaq listing is just awaiting the FDA decision now before they officially list on Nasdaq. An Abbott or similar partnership would also present better value in terms of dilution.

Ovarian cancer assay which is a $2 billion annual opportunity and would have the highest sensitivity and specificity (gold standard) has also not been partnered at this stage which will present real value by year end.

I think the lab news and the subsequent Pharma contracts are being completely discounted at this price.

Pharma services ‘alone’ are said to cover the entire companies costs circ. 5 years. They have a formidable workforce at AGL just waiting to facilitate a high period of growth.

Momentum is shifting and we are lucky enough to now play this ride and the Ovarian results before the FDA decision which has seen its perceived risk substantially reduced.

AGL has this and so much more to look forward, but this period of cooling off has done no harm to the longer term trajectory.

It has been said that the US understand the FDA process far better than us brits, and as has been eluded to, this request for information was ‘as expected’ and that they were on track for Q2. Only for a delay similar to that of others who have seen a comparitively small drop in the share price, this has presented one hell of an opportunity to buy more, an opportunity that I believe active US investors will also be keen to take advantage of.

- Pharma labs UK and US
- Pharma Contracts
- Ovarian Cancer Study
- Nasdaq listing
- Partnerships
- FDA decision
- Sample to answer upgrade
- Peer reviewed papers
- Ovarian cancer assay by year end

Plenty of corporate milestones to keep us entertained and more importantly to underpin the company and its future global multi billion dollar opportunities.

De-risked on the basis that in the event they were unable to answer the written question within 180 days they would have to withdraw the application, that is a massive milestone that didn’t come to the fore.

Also no requirements for bloods, and path to submission of data becoming of May. This also suggests that they are happy with data (bloods), another massive tick.